A Study of Durvalumab and Stereotactic Radiotherapy for Stage I Non-Small Cell Lung Cancer
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The SCION Trial is a clinical trial in patients with early stage non-small cell lung cancer.
The purpose of the trial is to investigate whether it is safe and effective to combine
standard radiation treatment with a drug called durvalumab, a type of immunotherapy. In
addition, the study will use a blood test to look for cancer cell DNA to determine how long
treatment with durvalumab should last. Both the use of durvalumab and the use of the blood
test are new strategies for managing early stage non-small cell lung cancer.